Biogen Idec Inc., the Cambridge-based biotechnology company that makes the multiple sclerosis drug Avonex, can spend at least $2 billion to expand in the markets for drugs that treat cancer and neurological disorders, the German newspaper Sueddeutsche Zeitung reported yesterday.
